866-997-4948(US-Canada Toll Free)

Neuroendocrine Tumors - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Oct 2013

Category :

Oncology

No. of Pages : 104 Pages


Global Markets Directs, \'Neuroendocrine Tumors Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Neuroendocrine Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroendocrine Tumors. Neuroendocrine Tumors Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Neuroendocrine Tumors.
  • A review of the Neuroendocrine Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Neuroendocrine Tumors pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Neuroendocrine Tumors Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Neuroendocrine Tumors 8
Neuroendocrine Tumors Therapeutics under Development by Companies 10
Neuroendocrine Tumors Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Neuroendocrine Tumors Therapeutics - Products under Development by Companies 17
Neuroendocrine Tumors Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Neuroendocrine Tumors Therapeutics Development 19
Tekmira Pharmaceuticals Corp. 19
Merck & Co., Inc. 20
Delcath Systems, Inc. 21
Ipsen S.A. 22
Novartis AG 23
Progenics Pharmaceuticals, Inc. 24
Threshold Pharmaceuticals, Inc. 25
OncoMed Pharmaceuticals, Inc. 26
Nobelpharma Co., Ltd. 27
Gradalis Inc. 28
Neuroendocrine Tumors - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
MK-2206 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
panobinostat - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
DG-3173 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
everolimus - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
everolimus - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
edotreotide Labeled Yttrium 90 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
edotreotide Labeled Yttrium 90 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
TH-302 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
lanreotide acetate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
melphalan - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
IT-139 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
vantictumab - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
177Lu-DOTA-TATE - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
pasireotide LAR - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Peptides For Cancer - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Neuroendocrine Tumors Therapeutics - Drug Profile Updates 74
Neuroendocrine Tumors Therapeutics - Dormant Products 95
Neuroendocrine Tumors - Product Development Milestones 96
Featured News & Press Releases 96
Sep 28, 2013: Ipsen : results from CLARINET Phase III clinical trial showed the antiproliferative effect of Somatuline in the treatment of non-functioning GEP-NETs 96
Sep 17, 2013: Ipsen announces positive top line results from phase III ELECT study of Somatuline in the control of symptoms in NET patients with a history of carcinoid syndrome 97
Aug 12, 2013: Tekmira commences Phase I/II study of TKM-PLK1 98
Jul 11, 2013: Ipsen announces positive results from phase III CLARINET study of Somatuline Autogel 120mg in gastrointestinal and pancreatic neuroendocrine tumors 99
Aug 06, 2012: Moffitt Cancer Center Researcher And International Colleagues Test New Drug For Patients With Neuroendocrine Tumors 100
Nov 29, 2011: Everolimus Prolongs Progression Free Survival For Patients With Neuroendocrine Tumors, MD Anderson Study Shows 100
Oct 07, 2008: Neotropix Receives Orphan Drug Designation For NTX-010 From FDA. 101
May 17, 2006: Neotropix Receives FDA Approval To Begin Clinical Trials With First Investigational Cancer Drug For NTX-010. 102

Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 104
Disclaimer 104

List of Table


Number of Products Under Development for Neuroendocrine Tumors, H2 2013 8
Products under Development for Neuroendocrine Tumors - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Late Stage Development, H2 2013 13
Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Clinical Stage Development, H2 2013 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 16
Products under Development by Companies, H2 2013 17
Products under Investigation by Universities/Institutes, H2 2013 18
Tekmira Pharmaceuticals Corp., H2 2013 19
Merck & Co., Inc., H2 2013 20
Delcath Systems, Inc., H2 2013 21
Ipsen S.A., H2 2013 22
Novartis AG, H2 2013 23
Progenics Pharmaceuticals, Inc., H2 2013 24
Threshold Pharmaceuticals, Inc., H2 2013 25
OncoMed Pharmaceuticals, Inc., H2 2013 26
Nobelpharma Co., Ltd., H2 2013 27
Gradalis Inc., H2 2013 28
Assessment by Monotherapy Products, H2 2013 29
Assessment by Stage and Route of Administration, H2 2013 31
Assessment by Stage and Molecule Type, H2 2013 33
Neuroendocrine Tumors Therapeutics - Drug Profile Updates 74
Neuroendocrine Tumors Therapeutics - Dormant Products 95

List of Chart


Number of Products under Development for Neuroendocrine Tumors, H2 2013 8
Products under Development for Neuroendocrine Tumors - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 12
Late Stage Products, H2 2013 13
Mid Clinical Stage Products, H2 2013 14
Early Clinical Stage Products, H2 2013 15
Pre-Clinical Stage Products, H2 2013 16
Assessment by Monotherapy Products, H2 2013 29
Assessment by Route of Administration, H2 2013 30
Assessment by Stage and Route of Administration, H2 2013 31
Assessment by Molecule Type, H2 2013 32
Assessment by Stage and Molecule Type, H2 2013 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *